Home | Coverage | Agents | Pulse | LogIn |
Darwin Score | +2 |
Ticker | MRK |
Latest Price | 111.25 EUR as of close on 04-Jul-2025 |
3 Month price range | 108.89 to 126.25 EUR |
Market Capitalisation | 48.13Bn EUR |
Country | Germany |
Region | Europe |
Economic Sector | Health Care |
Business Sector | Pharmaceuticals, Biotechnology & Life Sciences |
Industry | Pharmaceuticals |
Sub-Industry | Pharmaceuticals |
Description | Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG. See More ... |
Company URL | https://www.merckgroup.com/en |
See Darwins Full Analysis for Merck KGaA |
Tell Me About (TMA) is Darwins structured scoring system for assets. Here are the scores from the key TMA sections for Merck KGaA. Further information and full detail is available when you login.
TMA Part | Focus of Analysis | TMA Score |
---|---|---|
Price | Analysis of performance, trend, RSI, OBV and moving averages | -4 |
Sentiment | News and Candle Patterns. | +1 |
Fundamentals | Analyst Ratings, Valuation and Dividend analysis. | 0 |
Flow | Institutional, Fund and Insider buying and selling. | 0 |
Models | Forecast models. | +5 |
There are 5 live alerts for Merck KGaA.
There are 3 peers of Merck KGaA.
Asset Name | Industry Group | Perf(20d)% | Asset Score |
---|---|---|---|
Bayer AG (BAYN) | Pharmaceuticals | -1.4 | -12 |
Dermapharm Holding SE (DMP) | Pharmaceuticals | -2.3 | +21 |
Evotec SE (EVT) | Pharmaceuticals | +2.1 | +11 |
To see complete information on Merck KGaA or any other assets please login.
If you do not already have an account you can register for a free trial of our service. This will let you explore all the analytical information we have on price, fundamantals, flow, sentiments & models for all the stocks under coverage. You will then be able to compare asset scores and perform a wide range of multi asset analysis such as Market Cycles and Relative Scores.
©2025 Darwin Knows - All Rights Reserved |